Drugs / HDV-Insulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00814294 | Dec 2008 → Sep 2009 | diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-07 | Diasome Pharmaceuticals | Results Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes diasome.com ↗
Diasome reported that HDV-LIS maintained glycemic control with an A1C non-inferiority margin of <0.1% met at Weeks 12 and 25. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Diasome Pharmaceuticals | Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress diasome.com ↗ |
| 2026-06-07 | Diasome Pharmaceuticals | Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes diasome.com ↗ |
| 2026-05-26 | Diasome Pharmaceuticals | Diasome to Present Phase 2b Results from OPTI-2 Trial Evaluating HDV-Insulin Lispro in Type 1 Diabetes at ADA 86th Scientific Sessions diasome.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDV-Insulin | “Patients receive Oral HDV-Insulin (U-15).” NCT00814294 ↗ |